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Flabellaria paniculata Cav. (Malpighiaceae) is a climbing shrub, the preparations of
which are used in the treatment of wounds and ulcers in Nigeria and Ghana. This
study investigated the sub-chronic toxicity profile of the hydroethanolic leaf extract of
F. paniculata (HLE-FP). HLE-FP was administered p.o. (20, 100, and 500mg/kg) for 30
and 60 days to different groups of rats. Control animals received 10ml/kg distilled water.
In the group of animals for reversibility study, HLE-FP administration ceased on the 60th
day and animals were monitored for a further 15 days. Results showed that oral treatment
with HLE-FP for 30 days caused significant (p < 0.05) reductions in weight gain pattern
compared to control. These changes were sustained with 60 days treatment. However, no
significant (p > 0.05) differences in relative organ weights between control and treatment
groups were observed. HLE-FP-treated rats showed significant (p < 0.05) increases in Hb,
PCV and RBC on day 30 and significant (p < 0.05) increases in MCV and MCH indices
on day 60 compared to control. There were significant (p < 0.05) elevations in serum
K+, urea and creatinine compared to control. The liver function tests showed slight but
non-significant alterations in relevant parameters when compared to control. Biochemical
findings were supported by histopathological observations of vital organs including the
kidney and liver. Toxicities observed in respect of kidney function were irreversible at 15
days of stoppage of treatment. In the acute toxicity study, HLE-FP given p.o. caused
no lethality at 5000mg/kg but behavioral manifestations like restlessness, generalized
body tremor, feed, and water refusal were observed. The i.p. LD50 was estimated to be
2951.2mg/kg. Findings in this study showed that HLE-FP is relatively non-toxic on acute
exposure and generally safe on sub-chronic administration, but could be deleterious on
the kidneys on prolonged oral exposure at a high dose. Thus, caution should be exercised
with its long-term usage.
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INTRODUCTION
Mankind has relied on plants for food and medicines as early
as his emergence and this continues to be the case in this mod-
ern times. By WHO estimation, about 80% of the population in
developing countries depend on traditional medicine, most sig-
nificantly herbal remedies, for their primary healthcare (World
Health Organization, 2003; Campbell-Tofte et al., 2012). This is
very true for significant populations in Africa, Asia, and South
America especially. According to Leonti and Casu (2013), tra-
ditional medicine and medicinal plants are frequently used in
urban settings as alternatives in daily health care and for self-
medication against minor and chronic ailments, but especially
relied upon in less wealthy rural areas or in times of eco-
nomic crises. In recent times however, the faith in and patron-
age of herbal remedies has tremendously increased even in the
developed countries, as observed in Europe and North America.
According to Campbell-Tofte et al. (2012), plant-derived tra-
ditional medicines have become very lucrative business in the
international marketplace and annual revenues reported for the
sale of herbal medicines in Western Europe reached US$5 billion
in 2003–2004.
Amajor reason for the increasing patronage of herbal remedies
across the world, aside from belief of efficacy or proven efficacy, is
general perception of safety. A significant number of the general
public across the world hold the false perception that traditional
medicinal products are safer because they are prepared from nat-
ural sources without much processing (Calixto, 2000) and due
to history of long usage in the treatment of diseases accord-
ing to knowledge accumulated over centuries (Fennell et al.,
2004). However, it has been reported that many plants used as
food or in traditional medicine are potentially toxic, mutagenic
and carcinogenic based on reports of scientific research (Kassie
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et al., 1996; De Sã Ferrira and Ferrão Vargas, 1999; Fennell
et al., 2004). Adewunmi and Ojewole (2004) also reported
that some traditional, complementary, and alternative medicines
contain toxic and potentially lethal constituents which include
aristolochic acids, pyrrolizidine alkaloids, benzophenanthrine
alkaloids, lectins, viscotoxins, saponins, diterpenes, cyanogenic
glycosides and furanocoumarins.
According to Campbell-Tofte et al. (2012),WHO has called for
urgency in setting up international standards andmethods for the
evaluation of safety and therapeutic efficacy of traditional medic-
inal approaches, in recognition of the potential of traditional
medicine for providing treatment solutions for various infec-
tious and chronic diseases. Despite the fact that pharmacological
and toxicological evaluations of medicinal plants are essential for
drug/standardized herbal remedy development (Ibarrola et al.,
2000; Ahmed et al., 2006; Perera et al., 2010; Afolabi et al., 2012),
the reports of scientific investigations detailing efficacy based on
traditional claims far outnumber those of toxicological investi-
gations and toxicity. Verpoorte et al. (2005) and Campbell-Tofte
et al. (2012) have suggested that plant preparations and phyto-
chemicals derived from medicinal plants pre-selected in tradi-
tional medicine be investigated in vivo for their safety and efficacy
using carefully selected disease model animals, or in specially-
designed randomized and placebo-controlled clinical trials. It
is unarguable that safety evaluations of herbal remedies, espe-
cially to determine the consequence of prolonged use, are critical
to the discovery and development of standardized herbal reme-
dies and the acceptance of such by stakeholders in healthcare for
therapeutic application.
Flabellaria paniculata Cav. (Malpighiaceae) is a climbing
shrub, with gray-silky branchlets/leaves and white to light pink
flowers, widely distributed in equatorial Africa (from Senegal
to W Cameroons and Equatorial Guinea; and across the Congo
basin to Uganda and Tanzania) in thickets, woodlands, and
forests, especially along rivers (Hutchinson and Dalziel, 1958;
Burkill, 1997). The plant is locally called “Tinupogbe” and
“Ajidere” by the Yoruba people of Southwest Nigeria. In terms of
uses in traditional African medicine (TAM), preparations from
different parts of the plant are used for general healing (leaf), as
abortifacients, ecbolics; for menstrual cycle disorder (leaf-sap);
and as antidotes for venomous stings, bites etc. (root) (Burkill,
1997). According to Burkill (1997), the leaf is used in Ghana
and Nigeria on wounds and sores; in Ivory Coast the leaf-sap is
frequently taken for amenorrhea and as an ecbolic; the ground
root along with some other ingredients is used as a vaccine for
snake-bite in the Mampong area of Ghana. Based on the report of
Sofidiya et al. (2012), the leaves and root of F. paniculata are used
as ingredients of herbal preparations for the treatment of wound
and ulcers sold and prescribed in herbal stalls in Lagos metropolis
of Nigeria.
In terms of scientific evaluation, Abo and Olugbuyiro
(2004a,b) and Olugbuyiro et al. (2010) reported the wound heal-
ing and antibacterial activities of the leaf extracts of the plant.
Based on reported traditional use, Sofidiya et al. (2012) investi-
gated the effectiveness of the ethanolic leaf and root extracts of F.
paniculata in rat models of gastric ulcer. The authors concluded
that the ethanolic leaf extract and not the ethanolic root extract
possess antiulcer activity. Both extracts were found to contain
terpenoids, tannins and saponins but not alkaloids. Flavonoids
were reported to be additionally present in the leaf extract while
anthraquinones were detected in the root extract suggesting that
the antiulcer effect of the leaf extract may be associated with the
presence of flavonoids which are known to possess antioxidant
property.
In view of the wide application of leaf preparations of F. pan-
iculata in TAM and tendency for overuse and prolong intake,
this study was designed to investigate the possible dose and time-
dependent sub-chronic toxicity effects of the hydroethanolic leaf
extract of F. paniculata (HLE-FP) in rodents.
MATERIALS AND METHODS
PLANT COLLECTION
Fresh leaves of F. paniculata were collected from a decidu-
ous forest in Ilaro Town, Egbado Local Government Area of
Ogun State, Nigeria. The plant samples collected in July 2012
were identified and authenticated by Mr. TK Odewo, a for-
mer Senior Superintendent of the Forestry Research Institute
of Nigeria (FRIN), Ibadan, Nigeria, now Herbarium Curator in
the Department of Botany and Microbiology, Faculty of Science,
University of Lagos, Lagos, Nigeria. A voucher specimen num-
bered LUH 5009 was deposited in the institutional herbarium for
reference purposes.
PLANT EXTRACTION
The fresh leaves of F. paniculata were air-dried at room tem-
perature (23–25◦C) until a constant weight was consistently
obtained. The dried materials were ground into coarse powder
using Christy and Norris 8’ Laboratory Milling Machine (serial
no. 50158). One hundred gram of the dried leaf material wasmac-
erated in 1 L of hydroethanol (1:1) with continuous mechanical
stirring for 3 h after which the extract was decanted and filtered
using Whatman No. 1 paper. The process was repeated with the
residue and subsequent residue (×2) to ensure exhaustive extrac-
tion. The combined filtrate was evaporated to dryness under
vacuum on a rotary evaporator (Heidolph-Rotacool, Germany)
at 40◦C giving a deep brown, sweet-smelling solid residue. The
extract was reconstituted in normal saline before administration
to experimental animals.
PRELIMINARY PHYTOCHEMICAL ANALYSIS
This was carried out for the detection of various phytocon-
stituents according to the establishedmethod of Sofowora (1993).
EXPERIMENTAL ANIMALS
The animals used in this study, including young adult female
Wistar albino rats (6–8 weeks old; 80–125 g) and Swiss albino
mice (8–10 weeks old; 20–25 g) were obtained from the
Laboratory Animal Centre of the College of Medicine, University
of Lagos, Lagos, Nigeria.
The animals were housed in adequately ventilated hygienic
compartments, sustained under standard environmental condi-
tions (23–25◦C, 12 h/12 h light/dark cycle), and fed with standard
rodent diet (Livestock Feeds PLC, Ikeja, Lagos, Nigeria) and water
ad libitum. The cage beddings and water bottles were cleaned on
a daily basis. The animals were allowed 2 weeks of acclimatization
before the commencement of experimental procedures.
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The investigational procedures adopted in this study were in
accordance with the requirements of the Experimentation Ethics
Committee on Animal Use of the College of Medicine, University
of Lagos, Lagos, Nigeria and the United States National Academy
of Sciences Guide for the Care and Use of Laboratory Animals
[National Research Council (US) Committee for the Update of
the Guide for the Care and Use of Laboratory Animals, 2011].
ACUTE TOXICITY STUDIES
Acute oral (p.o.) toxicity study was carried out according to
the procedure of the limit dose test of Up-and-Down method
(OECD, 2008b) using a computer-guided statistical programme
(AOT425statPgm; version 1.0) at a limit dose of 5000mg/kg body
weight/oral route and default of Sigma at 0.5 (Adeneye et al.,
2006). Three female rats selected out of a population of 10 rats
using systematic randomization techniques, such that the weight
differences do not exceed ±10% of the mean initial weight of
the sample population, were used in this study. The animals were
observed at different time intervals for behavioral manifestations.
Acute intraperitoneal (i.p.) toxicity study was conducted
using the log dose-probit analysis method of Miller and Tainter
(Randhawa, 2009). Mice were randomly allotted to 6 groups of
5 mice each such that the weight difference within and between
groups does not exceed ±20% of the sample population. Mice
in the different groups were separately treated i.p. with normal
saline (10ml/kg) and HLE-FP at doses of 250, 500, 1000, 2000,
and 4000mg/kg. Animals were observed for 2 h post-treatment
for behavioral manifestations and mortality within 24 h post-
treatment was recorded for the respective groups. The median
lethal dose (LD50) was estimated using log dose-probit analysis.
SUB-CHRONIC ORAL TOXICITY STUDY
Sixty young adult female Wistar albino rats were randomly
divided into 4 major groups (I-IV) with each group sub-divided
into 3 sub-groups (A, B, and C) consisting of five rats each.
Treatment was then carried out in the different sub-groups as
outlined below:
IA and IB (high dose group): 500mg/kg/day p.o. HLE-FP for
30 and 60 days respectively.
IIA and IIB (medium dose group): 100mg/kg/day p.o.HLE-FP
for 30 and 60 days respectively.
IIIA and IIIB (low dose group): 20mg/kg/day p.o. HLE-FP for
30 and 60 days respectively.
IVA and IVB (control group): Normal saline 10ml/kg/day p.o.
for 30 and 60 days respectively.
IC, IIC, IIIC, and IVC (reversibility study): Normal saline
10ml/kg/day p.o. for 14 days after termination of extract treat-
ments on the 60th day.
BLOOD SAMPLE COLLECTION
A day prior to termination of each set of rats on days 31, 61,
and 75 of the experiment, the rats were fasted of feed but drink-
ing water was made available ad libitum. The rats were sacrificed
humanely under inhaled diethyl ether anaesthesia. After a deep
anaesthesia, each rat was mounted on dissecting board and a
deep longitudinal incision was made into the ventral surface of
the abdomen and thorax. By blunt dissection of the muscles
and fasciae, the contents of both the thorax and abdomen were
exposed. Blood sample was collected by cardiac puncture with a
21 G needle mounted on a 5ml syringe plunger. Blood sample
for full blood count was collected into EDTA-treated sample bot-
tle. Blood sample for serum biochemical assays was collected
into plain sample bottles, allowed 2 h to clot, and centrifuged
(Uniscope Laboratory Centrifuge; Model SM 902B, Surgifriend
Medicals, England, UK) at 3500 rpm for 10min to obtain the
serum. The serum collected was used to analyse parameters such
as alanine aminotransferase (ALT), aspartate aminotransferase
(AST), alkaline phosphatase (ALP), total protein (TP), albumin
(ALB), total cholesterol (TC), triglycerides (TG), high density
lipoprotein cholesterol (HDL-c), electrolytes (sodium, potas-
sium, calcium, bicarbonate and phosphates), urea and creatinine.
MEASUREMENT OF BODY AND ORGANWEIGHTS
The weight of all rats were taken using electronicMettler weighing
balance (Mettler Toledo Type BD6000, Mettler-Toledo GmbH,
Greifensee, Switzerland) on days 1, 15, 30, 45, 60, and 75.
For each animal, the % weight change was calculated as given
below:
% Weight change = (Difference between interval and initial
body weight ÷ Initial body weight) × 100
The mean of values for each group was then calculated to give %
weight change ± SD. At the end of the respective treatment peri-
ods, the rats were dissected (cut open from the abdominal cavity
to the thoracic cavity) under inhaled deep diethyl ether anaesthe-
sia and organs such as the lungs, spleen, stomach, heart, liver, and
kidneys were identified, cleared of adherent tissues and harvested.
The organs were then rinsed with normal saline, blotted with fil-
ter paper and weighed with electronic Mettler weighing balance.
The weight of each organ relative to 100 g of the body weight of
the rats from which the organs were harvested was calculated as:
[organ weight (g) ÷ body weight of rat (g)] × 100.
DETERMINATION OF SERUM BIOCHEMICAL PARAMETERS
ALT, AST, ALP, lipids (triglycerides, total cholesterol, HDL-c),
total protein, albumin, urea and creatinine were analyzed using
standard diagnostic test kits (Randox Laboratories, Crumlin, UK)
on Automated Clinical System (Sychron Clinical System®, model:
CX5 PRO; Beckman Coulter Inc., Galway, Ireland). Electrolytes
(sodium, potassium, chloride, calcium, bicarbonate, and phos-
phates) were determined using the ISE 6000 BYY SFRI spec-
trophotometer.
HEMATOLOGICAL ASSAYS
Full blood count (FBC) was determined using Hematology Auto-
analyzer System (Sysmex Hematology-Coagulation Systems®,
Model KX-21N, Sysmex Incorporation, Kobe, Japan).
HISTOPATHOLOGICAL ASSESSMENT
Selected organs were identified and carefully extracted. The tis-
sues were fixed in 10% buffered formalin, dehydrated in graded
alcohol (70, 90, 95, and 100%) and embedded in paraffin.
The embedded tissues were then cut into 4–5µm thick sec-
tions and stained with hematoxylin-eosin for photomicroscopic
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assessment using a Model N-400ME photomicroscope (CEL-
TECH Diagnostics, Hamburg, Germany). The histopathology
slides were viewed at various magnifications (×40, ×100,
and × 400) to detect pathological lesions.
STATISTICAL ANALYSIS
Data are expressed as mean ± SD for body and relative organ
weights while data for biochemical and hematological assays are
expressed as mean ± s.e.m. Statistical analysis was carried out
using One-Way Analysis of Variance (ANOVA) and Newman-
Keuls’ post hoc test. Level of statistical significance was considered
at values of p < 0.05.
RESULTS
PRELIMINARY PHYTOCHEMICAL ANALYSIS
Tannins, saponins, flavonoids, and presence of a steroidal nucleus
(i.e., aglycone portion of cardiac glycoside) were detected in
HLE-FP.
ACUTE TOXICITY STUDIES
Single oral treatment of rats with 5000mg/kg body weight of
HLE-FP produced no death within the short- and long-term
outcome of the limit dose test of Up-and-Down procedure.
Observed behavioral manifestations include dyspnoea, restless-
ness/agitation, generalized body tremor, feed and water refusal
within 24 h post-treatment p.o. These manifestations gradually
subsided after 24 h. The LD50 was estimated to be greater than
5000mg/kg body weight/oral route.
Single intraperitoneal treatment with HLE-FP at doses of 250,
500, 1000, 2000, and 4000mg/kg caused 0, 0, 0, 20, and 80%mor-
tality, respectively, in the treated mice within 24 h post-treatment.
Using log dose-probit analysis, the i.p. LD50 was estimated to
be 2951.2mg/kg. Behavioral manifestations sequel to i.p. admin-
istration of HLE-FP includes restlessness and writhing within
the first 15min, and calmness and anorexia within 48 h post-
treatment for surviving mice.
EFFECT OF HLE-FP ON THE BODY WEIGHT IN THE SUB-CHRONIC ORAL
TOXICITY STUDY
Table 1 shows the effect of repeated daily oral treatment with 20,
100, and 500mg/kg HLE-FP on the average body weight of rats
on days 1, 15, and 30, as well as percentage body weight changes
on day 30. Oral HLE-FP treatment for 30 days caused signifi-
cant (p < 0.05) reductions in the weight gain pattern of treated
rats in a non-dose-dependent manner with the highest reductions
recorded for Group III (20mg/kg) rats while the lowest weight
gain reduction was recorded for Group II (100mg/kg) rats.
Table 1 also shows the effect of repeated daily oral treatment
with 20, 100, and 500mg/kg of HLE-FP on the average body
weight of rats on days 45 and 60, as well as percentage body weight
changes of treated rats.
By the 60th day of the study, Group I rats treated with the high-
est dose of HLE-FP had the least weight gain pattern when com-
pared to untreated control values (Group IV rats) with the most
significant weight gain recorded for the Group II rats which were
treated with 100mg/kg/day HLE-FP. This observation suggests
that HLE-FP cause significant (p < 0.05) non-dose-dependent
weight loss effect on the treated rats.
EFFECT OF HLE-FP ON RELATIVE ORGANWEIGHT IN THE
SUB-CHRONIC ORAL TOXICITY STUDY
As shown in Table 2, there was no significant difference (p >
0.05) between control (normal saline) values and the HLE-FP
treatment groups values in the 30 and 60 days treatment periods.
This observation was same in the reversibility study.
EFFECT OF HLE-FP ON SERUM ELECTROLYTES, UREA AND CREATININE
LEVELS IN THE SUB-CHRONIC ORAL TOXICITY STUDY
Repeated daily oral treatment with 20–500mg/kg HLE-FP for
30 days caused non-significant and non-dose-dependent (p >
0.05) rise in serum Na+ concentration (Table 3). 20 and
100mg/kg HLE-FP also caused significant (p < 0.05) increases
in serum K+ and HCO−3 concentrations compared to control
values, respectively. However, 20–500mg/kg HLE-FP caused non-
significant (p > 0.05) alterations in the serum levels of urea and
creatinine.
Repeated oral treatments with 20–500mg/kg HLE-FP for 60
days was associated with dose-related reductions in the serum
levels of Na+ with the most significant (p < 0.05) reduction
recorded at 500mg/kg of HLE-FP while also causing dose-
dependent increase in the serum levels of K+ with the most
significant (p < 0.05) increase also recorded at 500mg/kg HLE-
FP compared to control values (Table 3). Oral treatment with
20mg/kg HLE-FP caused significant (p < 0.05) increase in the
serum level of HCO−3 while 20–500mg/kg HLE-FP caused signif-
icant (p < 0.05) increase in the serum levels of urea compared to
control values. However, oral treatment with 20–500mg/kg HLE-
FP for 60 days was associated with non-significant (p > 0.05)
alterations in the serum Cl− and creatinine levels.
Table 1 | Effect of HLE-FP on body weight in the sub-chronic oral toxicity study.
Group 1st day 15th day 30th day 30th day 45th day 60th day 60th day
wt. (g) wt. (g) wt. (g) %wt. wt. (g) wt. (g) %wt.
I 120.40±24.25 136.80±17.24 159.10±19.80 34.32±18.47a 173.60±18.00 187.40±20.74 55.65± 25.06a
II 108.80±7.45 134.70±08.09 153.80±21.04 41.67±21.04 164.10±18.19 191.20±16.71 71.92± 09.57a
III 121.80±17.10 144.00±19.42 161.30±18.71 28.02±32.16a 165.90±16.08 191.80±23.51 69.02± 29.44a
IV 86.33±23.40 129.30±16.31 151.10±12.40 85.62±44.65 163.30±11.05 175.20±18.83 102.94± 15.50
aRepresents a significant decrease at p < 0.05 compared to control values (Group IV).
I, 500mg/kg/day HLE-FP; II, 100mg/kg/day HLE-FP; III, 20mg/kg/day HLE-FP; IV, 10ml/kg normal saline.
Frontiers in Pharmacology | Ethnopharmacology April 2014 | Volume 5 | Article 78 | 4
Akindele et al. Toxicity study of Flabellaria paniculata
Ta
b
le
2
|E
ff
ec
t
o
f
H
LE
-F
P
o
n
re
la
ti
ve
o
rg
an
w
ei
g
h
t
in
th
e
su
b
-c
h
ro
n
ic
o
ra
lt
ox
ic
it
y
st
u
d
y.
G
ro
u
p
30
d
ay
s
tr
ea
tm
en
t
60
d
ay
s
tr
ea
tm
en
t
R
ev
er
si
b
ili
ty
st
u
d
y
Li
ve
r
S
to
m
ac
h
Lu
n
g
s
S
p
le
en
K
id
n
ey
s
H
ea
rt
Li
ve
r
S
to
m
ac
h
Lu
n
g
s
S
p
le
en
K
id
n
ey
s
H
ea
rt
Li
ve
r
S
to
m
ac
h
Lu
n
g
s
S
p
le
en
K
id
n
ey
s
H
ea
rt
I
3.
40
±
0.
48
1.
32
±
0.
23
0.
89
±
0.
23
0.
66
±
0.
11
0.
66
±
0.
11
0.
66
±
0.
11
4.
18
±
1.
05
1.
31
±
0.
29
0.
96
±
0.
35
0.
59
±
0.
04
0.
59
±
0.
04
0.
59
±
0.
04
2.
91
±
0.
24
1.
08
±
0.
12
1.
08
±
0.
37
0.
54
±
0.
06
0.
54
±
0.
06
0.
54
±
0.
06
II
4.
01
±
0.
37
3.
80
±
1.
27
0.
89
±
0.
40
0.
72
±
0.
08
0.
72
±
0.
11
0.
72
±
0.
11
3.
71
±
0.
79
1.
31
±
0.
29
1.
90
±
0.
92
0.
64
±
0.
02
0.
64
±
0.
02
0.
64
±
0.
02
2.
70
±
0.
20
1.
05
±
0.
08
1.
05
±
0.
08
0.
53
±
0.
04
0.
53
±
0.
04
0.
53
±
0.
04
III
4.
21
±
0.
34
3.
74
±
0.
50
1.
10
±
0.
48
0.
84
±
0.
29
0.
84
±
0.
29
0.
84
±
0.
29
3.
66
±
0.
31
1.
54
±
0.
28
1.
19
±
0.
09
1.
19
±
0.
49
1.
19
±
0.
49
1.
19
±
0.
49
3.
26
±
0.
29
1.
05
±
0.
32
1.
14
±
0.
33
0.
53
±
0.
06
0.
53
±
0.
06
0.
53
±
0.
06
IV
3.
49
±
0.
29
1.
29
±
0.
03
0.
64
±
0.
01
0.
65
±
0.
01
0.
65
±
0.
01
0.
65
±
0.
01
3.
85
±
0.
21
1.
20
±
0.
04
0.
84
±
0.
27
1.
21
±
0.
50
1.
21
±
0.
50
1.
21
±
0.
50
3.
54
±
0.
25
1.
15
±
0.
13
1.
20
±
0.
24
0.
58
±
0.
06
0.
58
±
0.
06
0.
58
±
0.
06
p
>
0.
05
co
m
pa
re
d
to
co
nt
ro
lv
al
ue
s
(G
ro
up
IV
).
I,
50
0
m
g/
kg
/d
ay
H
LE
-F
P
;I
I,
10
0
m
g/
kg
/d
ay
H
LE
-F
P
;I
II,
20
m
g/
kg
/d
ay
H
LE
-F
P
;I
V,
10
m
l/k
g
no
rm
al
sa
lin
e.
Ta
b
le
3
|E
ff
ec
t
o
f
H
LE
-F
P
o
n
se
ru
m
el
ec
tr
o
ly
te
s,
u
re
a
an
d
cr
ea
ti
n
in
e
le
ve
ls
in
th
e
su
b
-c
h
ro
n
ic
o
ra
lt
ox
ic
it
y
st
u
d
y.
G
ro
u
p
30
d
ay
s
tr
ea
tm
en
t
60
d
ay
s
tr
ea
tm
en
t
R
ev
er
si
b
ili
ty
st
u
d
y
N
a+
K
+
C
l−
H
C
O
− 3
U
re
a
C
re
at
in
in
e
N
a+
K
+
C
l−
H
C
O
− 3
U
re
a
C
re
at
in
in
e
N
a+
K
+
C
l−
H
C
O
− 3
U
re
a
C
re
at
in
in
e
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
g
/d
L)
(m
g
/d
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
g
/d
L)
(m
g
/d
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
m
o
l/
L)
(m
g
/d
L)
(m
g
/d
L)
I
13
9.
00
±
1.
67
6.
60
±
0.
34
10
5.
00
±
1.
18
18
.1
6
±
0.
99
7.
96
±
0.
74
43
.5
2
±
3.
14
14
0.
40
±
0.
61
b
8.
12
±
0.
12
a
10
4.
70
±
0.
48
20
.1
8
±
0.
67
6.
38
±
0.
27
a
60
.4
6
±
2.
09
14
2.
00
±
1.
00
4.
34
±
0.
09
b
10
3.
20
±
0.
86
20
.6
0
±
0.
75
6.
66
±
0.
20
57
.9
2
±
1.
88
a
II
14
2.
60
±
1.
54
7.
05
±
0.
25
10
3.
00
±
1.
74
23
.6
0
±
0.
25
a
6.
84
±
0.
70
36
.2
3
±
5.
30
14
1.
20
±
0.
88
7.
17
±
0.
25
10
7.
10
±
1.
00
21
.4
6
±
1.
20
7.
84
±
0.
16
a
66
.0
2
±
4.
81
14
5.
60
±
1.
03
5.
30
±
0.
26
10
6.
20
±
0.
37
21
.0
0
±
0.
55
7.
88
±
0.
14
a
57
.9
6
±
1.
18
a
III
14
0.
10
±
1.
54
8.
52
±
0.
42
a
10
3.
60
±
3.
09
18
.7
2
±
1.
78
8.
12
±
1.
16
31
.3
0
±
2.
37
14
4.
70
±
1.
04
6.
43
±
0.
34
10
6.
00
±
0.
93
23
.2
6
±
0.
70
a
8.
54
±
0.
12
a
67
.6
9
±
1.
92
14
3.
20
±
1.
02
4.
94
±
0.
34
b
10
3.
20
±
0.
86
20
.0
0
±
0.
63
8.
78
±
0.
31
a
52
.0
0±
1.
47
a
IV
13
6.
50
±
1.
92
6.
74
±
0.
42
10
4.
40
±
0.
68
19
.0
6
±
0.
83
6.
24
±
0.
54
38
.3
0
±
5.
79
14
4.
60
±
1.
46
6.
17
±
0.
33
10
4.
30
±
0.
40
19
.1
6
±
0.
77
5.
32
±
0.
09
60
.0
6
±
1.
81
14
4.
00
±
1.
84
6.
32
±
0.
44
10
4.
40
±
0.
81
17
.8
0
±
1.
69
6.
26
±
0.
16
45
.3
0
±
1.
98
a
an
d
b
re
pr
es
en
t
a
si
gn
ifi
ca
nt
in
cr
ea
se
an
d
de
cr
ea
se
at
p
<
0.
05
re
sp
ec
tiv
el
y,
co
m
pa
re
d
to
co
nt
ro
lv
al
ue
s
(G
ro
up
IV
).
I,
50
0
m
g/
kg
/d
ay
H
LE
-F
P
;I
I,
10
0
m
g/
kg
/d
ay
H
LE
-F
P
;I
II,
20
m
g/
kg
/d
ay
H
LE
-F
P
;I
V,
10
m
l/k
g
no
rm
al
sa
lin
e.
www.frontiersin.org April 2014 | Volume 5 | Article 78 | 5
Akindele et al. Toxicity study of Flabellaria paniculata
Table 4 | Effect of HLE-FP on other serum biochemical parameters in the sub-chronic oral toxicity study.
Group I II III IV
30 DAYS TREATMENT
ALT (U/L) 102.60±22.92 72.15±15.71 104.30±18.15 77.19± 13.28
AST (U/L) 573.40±89.40 440.80±61.18 508.90±49.72 507.20± 75.87
ALP (U/L) 113.70±33.20 145.60±18.45 151.70±12.38 139.10± 26.10
TP (mg/L) 78.64±1.64a 55.84±3.38b 63.22±3.10 68.66± 2.71
ALB (mg/L) 41.60±1.18 30.62±2.58 34.32±1.71 36.14± 1.61
TG (mg/L) 1.13±0.41a 1.13±0.13a 0.81±0.12 0.66± 0.03
TC (mg/L) 2.30±0.17 1.84±0.14 1.77±0.23 1.94± 0.11
HDL-c (mg/L) 31.20±4.27a 17.00±3.11 22.20±2.75 12.80± 2.44
60 DAYS TREATMENT
ALT (U/L) 70.56±22.92 78.90±15.64 128.40±1.00 91.96± 5.46
AST (U/L) 487.90±53.02 466.50±28.71 691.10±25.48 534.90± 39.48
ALP (U/L) 155.70±17.46 219.70±70.48 192.50±11.14 120.50± 2.41
TP (mg/L) 71.72±2.95a 77.46±1.37a 67.08±1.78 67.24± 1.21
ALB (mg/L) 40.24±2.07 38.26±1.19 33.66±0.30 37.62± 0.49
TG (mg/L) 1.11±0.08a 0.75±0.03 0.88±0.08 0.72± 0.04
TC (mg/L) 1.55±0.28 0.75±0.03 0.88±0.08 0.72± 0.04
HDL-c (mg/L) 19.40±0.75 19.40±0.81 21.60±0.87 19.20± 0.58
REVERSIBILITY STUDY
ALT (U/L) 88.57±7.81b 67.97±4.37b 90.98±3.91 92.62± 1.57
AST (U/L) 558.00±23.23 630.30±19.15 575.70±16.54 558.90± 27.60
ALP (U/L) 166.40±2.47 216.20±26.38a 186.70±7.24 147.70± 14.26
TP (mg/L) 66.56±1.13 69.96±0.77 70.96±2.26 70.04± 1.19
ALB (mg/L) 36.58±1.28 39.18±0.61 38.78±1.04 37.02± 0.41
TG (mg/L) 0.98±0.06 0.85±0.03 0.99±0.07 0.92± 0.03
TC (mg/L) 2.27±0.20 1.77±0.05 1.85±0.07 2.10± 0.18
HDL-c (mg/L) 19.80±1.46 25.80±2.42 22.40±1.12 22.60± 2.14
a and b represent significant increase and decrease at p < 0.05 compared to control values, respectively.
I, 500mg/kg/day HLE-FP; II, 100mg/kg/day HLE-FP; III, 20mg/kg/day HLE-FP; IV, 10ml/kg normal saline.
Withdrawal of repeated daily oral treatment with
20–500mg/kg HLE-FP for 15 days caused reductions in the
serum K+ concentration, significantly (p < 0.05) at doses of 500
and 20mg/kg compared to the control value (Table 3). However,
withdrawal of HLE-FP from the treated rats for 15 days was asso-
ciated with significant (p < 0.05) and persistent increase in serum
urea concentrations at 20 and 100mg/kg when compared to the
control value. Also, there was significant (p < 0.05) increase
in the serum creatinine concentrations in all the treatment
groups compared to the control value. On Na+, Cl− and HCO−3
concentrations, withdrawal of HLE-FP caused non-significant
alterations in serum levels compared to control values.
EFFECT OF HLE-FP ON OTHER SERUM BIOCHEMICAL PARAMETERS IN
THE SUB-CHRONIC ORAL TOXICITY STUDY
Repeated oral treatment with 500mg/kg HLE-FP for 30 days
was associated with significant (p < 0.05) increases in the serum
total protein, triglyceride and high density cholesterol levels when
compared to control values (Table 4). HLE-FP at 100mg/kg also
caused significant (p < 0.05) increase in serum triglyceride and
decrease in serum total protein compared to control values.
However, HLE-FP at 20–500mg/kg caused non-significant (p >
0.05) alterations in the serum levels of ALT, AST, ALP, albumin
and total cholesterol compared to control values.
Repeated oral treatment at 20mg/kg of HLE-FP for 60 days
was associated with non-significant (p > 0.05) increase in the
serum ALT and AST levels, while there was also a non-significant
(p > 0.05) decrease in the serum ALT and AST levels at 100
and 500mg/kg HLE-FP compared to control values (Table 4).
500mg/kg HLE-FP also caused significant (p < 0.05) increases
in the serum levels of triglyceride and total cholesterol com-
pared to control values. HLE-FP at doses of 100 and 500mg/kg
also significantly (p < 0.05) elevated total protein serum level
compared to control values. However, oral treatment with
20–500mg/kg HLE-FP for 60 days caused non-significant (p >
0.05) alterations in the serum albumin and high density choles-
terol levels compared to control values. In respect of ALP, non-
significant increases were observed at all HLE-FP doses relative to
control.
Withdrawal of oral treatment with HLE-FP was associated
with significant (p < 0.05) reduction in the serum levels of ALT at
doses of 100 and 500mg/kg HLE-FP compared to control values
(Table 4). Also, withdrawal of oral treatment with HLE-FP for 15
days was associated with non-significant (p > 0.05) alterations in
the serum levels of AST, total protein, albumin, triglyceride, total
cholesterol and high density cholesterol.
EFFECT OF HLE-FP ON HEMATOLOGICAL PARAMETERS IN THE
SUB-CHRONIC ORAL TOXICITY STUDY
Repeated oral treatment with HLE-FP for 30 days was associ-
ated with significant (p < 0.05) increase in Hb, PCV and RBC
at 500mg/kg compared to control values (Table 5).
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Table 5 | Effect of HLE-FP on hematological parameters in the sub-chronic oral toxicity study.
Group I II III IV
30 DAYS TREATMENT
Hb (g/dL) 13.28±0.15a 11.24±0.22 10.76±0.64 11.26±0.29
PCV (%) 48.58±1.03a 42.96±1.47 38.78±2.01 41.66±0.72
RBC (×106/L) 8.13±0.22a 7.03±0.27 6.38±0.31 6.69±0.08
MCV (fL) 59.86±1.08 61.12±0.83 60.80±1.23 62.30±1.29
MCH (pg) 16.36±0.40 16.60±0.77 17.04±0.91 16.84±0.39
PLT (×103/L) 637.80±200.10 584.20±54.64 648.20±34.89 667.80±41.56
WBC (×103/L) 10.72±1.56 14.12±2.59 12.62±2.31 17.36±1.95
%LYM 72.92±3.03 85.88±0.96 83.76±4.14 79.18±6.30
%NEU 16.34±2.38 8.46±0.71 10.18±3.15 11.32±3.21
%MXD 10.74±0.90 5.66±0.60 6.06±1.13 9.50±3.18
60 DAYS TREATMENT
Hb (g/dL) 12.68±0.33 13.06±0.38 11.66±0.78 12.08±0.29
PCV (%) 45.80±1.23 44.88±1.17 43.96±1.48 44.08±1.29
RBC (×106/L) 7.82±0.12 7.73±0.15 7.95±0.21 8.01±0.37
MCV (fL) 58.50±0.74a 58.02±0.89a 55.32±0.79 54.28±0.69
MCH (pg) 16.20±0.26a 16.90±0.35a 15.24±0.29 15.18±0.40
PLT (×103/L) 621.20±44.94 706.80±73.92 696.40±97.85 473.40±38.06
WBC (×103/L) 14.18±1.29 12.24±0.86 14.60±1.15 14.02±2.03
%LYM 83.06±1.78 77.56±3.35 75.02±3.95 81.42±2.23
%NEU 10.34±1.78 14.76±2.85 18.26±4.28 12.50±2.44
%MXD 6.60±0.48 7.68±1.04 6.72±1.07 6.08±0.82
REVERSIBILITY STUDY
Hb (g/dL) 12.18±0.17 12.26±0.31 12.48±0.93 12.62±0.42
PCV (%) 47.88±3.80 50.14±1.41 50.46±1.18 49.12±0.91
RBC (×106/L) 7.22±0.53 7.76±0.19 11.13±1.75 7.90±0.12
MCV (fL) 66.26±1.38 64.66±1.19 61.36±0.97 62.22±0.17
MCH (pg) 17.34±1.65 15.82±0.30 15.20±0.18 15.96±0.27
PLT (×103/L) 710.20±29.53 606.40±66.64 710.00±187.10 726.40±30.86
WBC (×103/L) 14.38±3.23 9.72±0.47 12.20±1.58 16.08±1.76
%LYM 85.18±1.46 85.14±2.37 85.00±2.59 77.76±0.96
%NEU 4.94±0.32 5.76±0.83 3.71±0.67b 6.25±0.09
%MXD 9.88±1.65 9.10±1.60 11.48±1.87 16.02±1.03
a and b represent significant increase and decrease at p < 0.05 compared to control values, respectively.
I, 500mg/kg/day HLE-FP; II, 100mg/kg/day HLE-FP; III, 20mg/kg/day HLE-FP; IV, 10ml/kg normal saline.
By the 60th day of oral treatment with 20–500mg/kg HLE-
FP, there were significant (p < 0.05) increases in MCV and
MCH indices at 100 and 500mg/kg compared to control values
(Table 5).
Withdrawal of oral treatment withHLE-FP for 15 days resulted
in the reversal of earlier elevated hematological indices on 30th
(Hb, PCV and RBC) and 60th (MCV and MCH) days with values
comparable and not significantly different (p > 0.05) from con-
trol values (Table 5). All other measured hematological param-
eters were not significantly (p > 0.05) different from control
except for %NEU in respect of which a significant reduction
(p < 0.05) was observed at the dose of 20mg/kg compared to the
control value.
HISTOPATHOLOGICAL ASSESSMENT
Repeated oral treatment with 20–500mg/kg HLE-FP for 30
days was associated with increasing alveolar septa thickness
and reduction in alveolar space compared to control lungs
(Figure 1). However, no significant histological lesions were
observed in respect of the liver, stomach, kidneys, spleen and
heart.
With prolonged oral treatment with 20–500mg/kg HLE-
FP for 60 days, there were scattered areas of lymphocytic
aggregates with varying degrees of sinusoidal congestion sig-
nifying mild-to-moderate inflammatory process in the liver
compared to the control liver (Figure 2). The kidneys also
showed glomeruli with capillary vascular congestion and scat-
tered areas of haemorrhage compared to the control kidney
(Figure 3). In respect of the heart, few lymphocytic infil-
trations around the cardiac myocytes and fascicules were
observed in the 20mg/kg/day HLE-FP-treated group while occa-
sional lymphocytic aggregates were observed around the car-
diac myocytes in the 500mg/kg/day HLE-FP-treated group
compared to control (Figure 4). There were no remarkable
histopathological changes observed in the lungs, stomach, and
spleen.
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FIGURE 1 | Representative sections of rat lungs in respect of 30 days
treatment. (A) Normal rat lung showing normal alveoli and lung
parenchyma; (B) 20mg/kg/day HLE-FP-treated lung showing hyperplasia of
the alveolar septae resulting in thickened alveolar space; (C) 100mg/kg/day
HLE-FP-treated lung showing alveolar space smaller than that of control;
and (D) 500mg/kg/day HLE-FP-treated lung showing alveolar space
remarkably smaller than that of control (×100 magnification).
FIGURE 2 | Representative sections of rat liver in respect of 60 days
treatment. (A) Normal rat liver showing normal hepatic architecture; (B)
20mg/kg/day HLE-FP-treated rat liver showing patchy areas of lymphocytic
infiltrations; (C) 100mg/kg/day HLE-FP-treated rat liver showing mild
vascular congestion; and (D) 500mg/kg/day HLE-FP-treated rat liver
showing scattered areas of lymphocytic aggregates with mild sinusoidal
congestion signifying mild-to-moderate inflammation (× 100 magnification).
FIGURE 3 | Representative sections of rat kidneys in respect of 60 days
treatment. (A) Normal rat kidney showing regular tubular cells with normal
nuclei; (B) 20mg/kg/day HLE-FP-treated rat kidney showing glomeruli with
capillary vascular congestion; (C) 100mg/kg/day HLE-FP-treated rat kidney
showing regular glomeruli with scattered localized hemorrhage; and (D)
500mg/kg/day HLE-FP-treated rat kidney showing regular glomeruli and
tubules with moderate vascular congestion (× 100, × 400 magnification).
FIGURE 4 | Representative sections of rat heart in respect of 60 days
treatment. (A) Normal rat heart showing normal cardiac myocytes and
fascicules; (B) 20mg/kg/day HLE-FP-treated rat heart showing few
lymphocytic infiltrations around the cardiac myocytes and fascicules; (C)
100mg/kg/day HLE-FP-treated rat heart showing no remarkable histological
lesions; and (D) 500mg/kg/day HLE-FP-treated rat heart showing occasional
lymphocytic aggregates around the cardiac myocytes (× 100 magnification).
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FIGURE 5 | Representative sections of rat liver in respect of
reversibility study. (A) Normal rat liver showing normal hepatocytes and
hepatic vasculature; (B) 20mg/kg/day HLE-FP-treated rat liver showing
epithelial proliferation and scattered areas of vascular congestion; (C)
100mg/kg/day HLE-FP-treated rat liver showing scattered areas of vascular
congestion; and (D) 500mg/kg/day HLE-FP-treated rat liver showing few
local lymphocytic aggregates with mild-to-moderate vascular congestion
(× 100 magnification).
EFFECT OF 15 DAYS TOXICITY REVERSIBILITY OF ORAL TREATMENT
WITH 20–500mg/kg/DAY OF HLE-FP ON HISTOPATHOLOGY OF
SELECTED VITAL ORGANS OF TREATED RATS
No remarkable histological changes were observed in the lungs,
stomach, spleen, and heart. However, persistent few focal lym-
phocytic infiltrations with varying mild-to-moderate vascular
congestion were observed in the liver (Figure 5) while varying
degrees of glomerular congestions were observed in the kidneys
(Figure 6).
DISCUSSION
Toxicity studies have always been considered a vital integral
component of drug development bearing in mind that herbal
medicines are often used indiscriminately without recourse to the
potential side-effects which could vary from being mild, moder-
ate, and severe, to life-threatening (World Health Organization,
1987, 2000). In the present study, the acute and sub-chronic
toxicity, and toxicity reversibility profile of the hydroethanolic
leaf extract of F. paniculata cav. (HLE-FP) were evaluated in
rodents using anthropometric, biochemical, hematological and
histopathological parameters.
The results of acute oral and intraperitoneal toxicity studies
showed the LD50 values of HLE-FP to be greater than 5000mg/kg
and 2951.2mg/kg, respectively. The limit test is primarily used in
situations where the investigator has information indicating that
the test material is likely to be non-toxic or of low toxicity (OECD,
2002a,b) considering the fact that studies have shown that extracts
with acute oral LD50 value of greater than 3000–5000mg/kg can
be considered relatively safe (Chan et al., 1982; Itthipanichpong
FIGURE 6 | Representative sections of rat kidneys in respect of
reversibility study. (A) Normal rat kidney showing regular tubular cells with
normal nuclei; (B) 20mg/kg/day HLE-FP-treated rat kidney showing focal
area of epithelial cell proliferation; (C) 100mg/kg/day HLE-FP-treated rat
kidney showing congested vascular channels and areas of hemorrhage; and
(D) 500mg/kg/day HLE-FP-treated rat kidney showing localized hemorrhage
and glomerular capillary congestion (×100, × 400 magnification).
et al., 1987; OECD, 2008a). Thus, the high LD50 values obtained
for HLE-FP in this study are strong pointers to the fact that HLE-
FP could be considered safe on acute exposure to the extract.
Sub-chronic oral treatment with 20–500mg/kg/day of HLE-FP
over the period of 60 days was associated with significant decrease
in the weight gain pattern of HLE-FP-treated rats in a non-
dose dependent manner. This result suggests that HLE-FP may
be having weight losing effect mediated through either appetite-
inhibiting or nutrient losing mechanisms. Unfortunately, in this
present study, the food consumption pattern of HLE-FP-treated
rats was not investigated and this would have provided insight
into the possible weight losing potential of HLE-FP. However,
literature has shown that saponins cause weight loss through
appetite inhibition and inhibition of nutrients absorption from
the intestinal lumen (Ajagbonna et al., 1999). Thus, the presence
of saponins alone or in combination with other weight-losing
phytoconstituents in HLE-FP could account for the weight losing
effect of HLE-FP.
On repeated daily exposure of rats to HLE-FP for 30 days, there
was profound increment in hematological parameters such as
hemoglobin, hematocrit and red blood cell counts without signif-
icant alterations to all other measured hematological parameters
at the dose of 500mg/kg HLE-FP. By the 60th day of repeated oral
treatment, there was increment in the mean corpuscular volume
and mean corpuscular hemoglobin still at the dose of 500mg/kg
HLE-FP. However, these increments in the hematological param-
eters were reversed to about normal after oral treatment with
HLE-FP was stopped. This observation strongly suggests that
HLE-FP could have stimulatory effect on the pluripotent red cell
lines in the bone marrow. Further studies will still be required to
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validate this hypothesis. The hematopoietic system is one of the
most sensitive targets of toxic compounds and it is thus consid-
ered an important index of physiological and pathological status
in man and animals (Feldman et al., 2000; Adeneye et al., 2006).
Also, hematological parameters provide vital information regard-
ing the status of bone marrow activity and intravascular effects
such as hemolysis and anemia (Voigt, 2000).
On the liver function, sub-chronic effects of 20–500mg/kg/day
of HLE-FP were also evaluated. Oral treatment with
500mg/kg/day HLE-FP for 30 days was observed to have
resulted in profound elevation in the serum levels of total
protein, triglyceride, and high density cholesterol and total
cholesterol which were sustained over additional 30 days.
However, there were no significant alterations in serum liver
enzymes (ALT, AST, and ALP) values and other hepatic func-
tion parameters such as total protein and albumin, indicating
that HLE-FP did not cause deterioration in the liver function.
Although these biochemical results appear to be at variance
with that of its histopathology which showed scattered areas
of lymphocytic aggregates with mild sinusoidal congestion, it
could mean that the histological lesions were not severe enough
so as to have reflected in the measured hepatic enzyme markers
and other hepatic function tests. The liver is known to be the
main organ of detoxification for most drugs and alterations
in its enzyme markers are considered strong indicators of
toxicity profile of a drug (Woodman, 1996). Thus, the fact
that HLE-FP caused no significant alterations in these hepatic
enzyme markers suggest that HLE-FP is not hepatotoxic since
hepatotoxicity is marked by profound elevations in the serum
levels of ALT, AST, ALP and at times reduced serum total
protein and albumin levels (Caisey and King, 1980; Woodman,
1996).
On the renal function integrity, repeated daily oral treatment
with 20–500mg/kg/day HLE-FP for 30 days was associated with
significant elevation in the serum potassium and bicarbonate lev-
els with no alterations in other parameters such sodium, chloride,
urea and creatinine. With further oral treatment for additional
30 days, there were profound elevations in the serum potassium,
bicarbonates, and urea levels suggesting deleterious effect on the
renal function. The compromise in the renal function was corrob-
orated by the histopathological findings which showed areas of
localized hemorrhage and glomerular capillary congestion. Renal
functions are measured by serum electrolytes, urea and creati-
nine, thus, elevations in the serum levels of these parameters
are indicative of renal injury or insult (Caisey and King, 1980;
Woodman, 1996; Levine, 2002). These changes were irreversible
with the extract withdrawal for 15 days.
CONCLUSION
The results obtained in this study suggest that although HLE-
FP may be non-toxic on acute exposure and generally safe on
sub-chronic administration, this herbal preparation may have
deleterious effects on renal functions of rats treated with it over
a prolonged period of time with these toxicities being irreversible
with withdrawal of the extract for 15 days. These observations
suggest that decoction made from the leaf of F. paniculata should
be used with caution in order to avoid renal toxicities.
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